<div id="readability-page-1"><p><span>Teladoc Health (NYSE:TDOC - Get Free Report)</span> had its price objective cut by Citigroup  from $11.00 to $8.75 in a research report issued on Friday,Benzinga reports. The firm presently has a &#34;neutral&#34; rating on the health services provider's stock. Citigroup's price objective would indicate a potential upside of 21.61% from the company's previous close.</p><div><p><span></span><span>Get <strong>Teladoc Health</strong> alerts:</span></p></div><ul><li>2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick</li></ul><p>TDOC has been the subject of several other research reports. Oppenheimer decreased their price objective on shares of Teladoc Health from $14.00 to $12.00 and set an &#34;outperform&#34; rating for the company in a research note on Friday, January 24th. The Goldman Sachs Group dropped their price target on Teladoc Health from $16.00 to $13.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, March 3rd. Royal Bank of Canada boosted their price objective on Teladoc Health from $11.00 to $12.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, January 24th. Jefferies Financial Group lowered their target price on shares of Teladoc Health from $10.00 to $8.00 and set a &#34;hold&#34; rating on the stock in a research report on Monday. Finally, Needham &amp; Company LLC  reiterated a &#34;hold&#34; rating on shares of Teladoc Health in a research report on Thursday, February 27th. Twelve analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Hold&#34; and an average price target of $10.71.</p><p><b>View Our Latest Stock Report on TDOC</b></p><h2>Teladoc Health Stock Down 0.9 %</h2><ul><li>2 Former Pandemic Darlings Eyeing a Big 2025 Turnaround</li></ul><p>Teladoc Health stock traded down $0.07 during midday trading on Friday, reaching $7.20. The company's stock had a trading volume of 466,899 shares, compared to its average volume of 6,220,314. The business has a 50-day simple moving average of $8.63 and a 200-day simple moving average of $9.58. The company has a market cap of $1.26 billion, a P/E ratio of -1.25 and a beta of 1.73. Teladoc Health has a fifty-two week low of $6.35 and a fifty-two week high of $15.21. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. </p><p>Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.07). Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The business had revenue of $640.49 million during the quarter, compared to analyst estimates of $639.44 million.  On average, research analysts expect that  Teladoc Health will post -1.16 earnings per share for the current fiscal year. </p><h2>Insider Activity at Teladoc Health</h2><ul><li>Doximity: The 'Facebook for Doctors'  Surges After Earnings Beat</li></ul><p>In related news, insider Adam C. Vandervoort sold 11,011 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $8.42, for a total value of $92,712.62. Following the sale, the insider now directly owns 64,308 shares of the company's stock, valued at approximately $541,473.36. This represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 0.58% of the stock is currently owned by company insiders. </p><h2>Institutional Trading of Teladoc Health</h2><p>Several large investors have recently modified their holdings of TDOC. Golden State Wealth Management LLC lifted its stake in  Teladoc Health by 102.6% in the 1st quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider's stock valued at $27,000 after buying an additional 1,690 shares in the last quarter.  Versant Capital Management Inc boosted its stake in shares of  Teladoc Health by 313.8% during the fourth quarter. Versant Capital Management Inc now owns 3,219 shares of the health services provider's stock valued at $29,000 after acquiring an additional 2,441 shares during the last quarter.  Whipplewood Advisors LLC purchased a new stake in  Teladoc Health during the 4th quarter worth about $29,000.  Lindbrook Capital LLC raised its stake in  Teladoc Health by 78.9% in the 4th quarter. Lindbrook Capital LLC now owns 3,654 shares of the health services provider's stock valued at $33,000 after purchasing an additional 1,612 shares during the last quarter.  Finally, Sterling Capital Management LLC lifted its holdings in  Teladoc Health by 776.7% in the 4th quarter. Sterling Capital Management LLC now owns 4,629 shares of the health services provider's stock valued at $42,000 after purchasing an additional 4,101 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Teladoc Health</h2> (Get Free Report)<p>Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.</p><h2>See Also</h2><ul><li>Five stocks we like better than Teladoc Health</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Short Sellers Gave Up on These 3 Names Recently</li><li>3 Ways To Invest In Coffee, Other Than Drinking It</li><li>3 Boring Stocks Outperforming the Market This Year</li><li>Insider Trading - What You Need to Know</li><li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRET0M?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRET0M"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Teladoc Health Right Now?</h2><p>Before you consider Teladoc Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.</p><p>While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TDOC

<p>Citigroup has lowered its price target for Teladoc Health (NYSE:TDOC) from $11.00 to $8.75, maintaining a "neutral" rating. This adjustment suggests a potential upside of 21.61% from the previous close. Other analysts have also revised their targets, with Oppenheimer setting it at $12.00 and Goldman Sachs at $13.00. Currently, Teladoc's stock is trading at $7.20, down 0.9%, with an average rating of "Hold" and a price target of $10.71 from twelve analysts. The company reported a loss of $0.28 EPS in its last quarter, missing estimates.</p>

Citigroup Cuts Teladoc Health (NYSE:TDOC) Price Target to $8.75